Last reviewed · How we verify
ASK120067
ASK120067 is an investigational therapeutic agent in phase 3 development by Jiangsu Aosaikang Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
At a glance
| Generic name | ASK120067 |
|---|---|
| Also known as | Limertinib |
| Sponsor | Jiangsu Aosaikang Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available clinical trial data or mechanism disclosures, the precise molecular target and pharmacological action of ASK120067 remain unknown. The drug is currently in phase 3 clinical development, indicating it has progressed beyond early-stage testing but full mechanistic details are typically proprietary until regulatory submission or publication.
Approved indications
Common side effects
Key clinical trials
- Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases (PHASE2)
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067 (PHASE1)
- A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. (PHASE2)
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC (PHASE3)
- Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole (PHASE1)
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer (PHASE1, PHASE2)
- Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |